BACK TO TOP

Clinical Trials

Criterium Inc, Global CRO and The Oncology Consortia of Criterium are currently collaborating with our investigators and leading pharmaceutical partners on a number of exciting trials.


Criterium Inc GLOBAL CRO clinical research trials:

Critical Limb Ischemia / Ph II
A clinical study to assess blood-bourne autologous angiogenic precursors therapy in patients with critical limb ischemia
Clinical Trials.gov Trial ID NCT02140931

Squamous Cell Carcinoma of the Head, Neck, or Skin / Ph II
Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS
Clinical Trials.gov Trial ID NCT02449681

Acute Otitis Media / Ph III -- CLOSED for RECRUITING
Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients
Clinical Trials.gov Trial ID NCT01395966

Multiple Myeloma / Ph I -- CLOSED for RECRUITING
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma, or Diffuse Large B Cell Lymphoma
Clinical Trials.gov Trial ID NCT01435720

Infectious Disease / Ph II -- CLOSED for RECRUITING
Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients
Clinical Trials.gov Trial ID NCT01417780

Burn Wound Study / Ph IV -- CLOSED for RECRUITING
Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns
Clinical Trials.gov Trial ID NCT01654094

Leukemia/Lymphoma / Ph IIa -- CLOSED for RECRUITING
Multicenter, Open-label Study Designed to Evaluate the Safety and Efficacy of Escalating Doses of BL-8040 in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Clinical Trials.gov Trial ID NCT01838395

Necrotizing Fasciitis / Ph III
Randomized, double-blind, placebo-controlled, parallel-group, study of AB103 as compared to placebo in patients with necrotizing soft tissue infections (NSTI)

Hypogonadal Men / Ph IV -- CLOSED for RECRUITING
Randomized, placebo-controlled, double-blind study of transdermal treatment for elderly men with low serum testosterone concentrations


Myeloma Consortium clinical research trials at AMyC member and affiliate sites:

Relapsed/Refractory Multiple Myeloma / Ph I -- CLOSED for RECRUITING
IMGN901 in Combination with Lenalidomide and Dexamethasone in Patients with CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Clinical Trials.gov Trial ID NCT00991562

Relapsed/Refractory Multiple Myeloma / Phase I/II
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Clinical Trials.gov Trial ID NCT01464034

Newly Diagnosed Multiple Myeloma / Ph Ib -- CLOSED for RECRUITING
A Safety Study of Carfilzomib With Cyclophosphamide and Dexamethasone Prior to Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma.
Clinical Trials.gov Trial ID NCT01660750

Systemic Light Chain Amyloidosis / Ph I
A Safety Study of Carfilzomib in Patients with Previously-Treated Systemic Light Chain Amyloidosis.
Clinical Trials.gov Trial ID NCT01789242


GI Cancer Consortium clinical research trials at AGICC member and affiliate sites:

Perioperative Therapy for Resectable Pancreatic Cancer / Ph II -- OPEN for RECRUITING
Estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).
Clinical Trials.gov Trial ID NCT02723331

Colorectal-Gastric-Esophageal Cancers / Ph II -- OPEN for RECRUITING
Multicenter, single-arm study of oral ceritinib (LDK378) in adult patients with ALK-activated gastrointestinal malignancies
Clinical Trials.gov Trial ID NCT02638909

Pancreatic Cancer / Ph III -- CLOSED for RECRUITING
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (ONTRAC)
Clinical Trials.gov Trial ID NCT01360853

Metastatic Colorectal Cancer / Ph II
Dose Finding Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan (as a second treatment)
Clinical Trials.gov Trial ID NCT01116271
See the poster for this trial that was presented at ASCO

Stage IV, Measurable Colorectal Cancer/ Ph II
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
Clinical Trials.gov Trial ID NCT00912743
See the poster for this trial that was presented at ASCO



Lung/Thoracic Cancer Consortium clinical research trials at ATOMIC member and affiliate sites:

EGFR-Mutant, T790M-Negative, Advanced NSCLC / Ph II
A clinical study to evaluate antitumor activity as determined by response rate in patients with EGFR-mutant, T790M-negative, advanced NSCLC progressing on an EGFR TKICancer

Refractory ALK Rearranged NSCLC / Ph II
Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors
Clinical Trials.gov Trial ID NCT02449681


BREAST Cancer Consortium clinical research trials at ABRCC member and affiliate sites:

Breast CA with Brain Mets / Ph II
Open-Label, Multi-Center Study in Breast Cancer Patients with Recurrent Brain Metastases
Clinical Trials.gov Trial ID NCT02048059

 

 

GET TO KNOW US!

DOWNLOAD OUR BROCHURE